Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Instill Bio Inc | TIL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.40 | 07:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 10.40 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 6.07 - 14.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 10.40 | USD |
Instill Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 67.64M | 6.50M | - | 0 | -156.09M | -24.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Instill Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TIL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.35 | 10.78 | 10.15 | 10.55 | 8,907 | 0.05 | 0.48% |
| 1 Month | 10.62 | 11.23 | 10.15 | 10.67 | 10,344 | -0.22 | -2.07% |
| 3 Months | 11.65 | 12.98 | 10.15 | 11.53 | 14,502 | -1.25 | -10.73% |
| 6 Months | 8.00 | 12.98 | 6.07 | 7.30 | 148,696 | 2.40 | 30.00% |
| 1 Year | 12.632 | 14.00 | 6.07 | 9.63 | 342,514 | -2.23 | -17.67% |
| 3 Years | 340.00 | 473.60 | 6.07 | 108.47 | 509,375 | -329.60 | -96.94% |
| 5 Years | 540.00 | 589.80 | 6.07 | 118.55 | 507,077 | -529.60 | -98.07% |
Instill Bio Description
| Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. |
